The Non-alcoholic Fatty Liver Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-alcoholic Fatty Liver Disease pipeline products will significantly revolutionize the Non-alcoholic Fatty Liver Disease market dynamics.
DelveInsight’s “Non-alcoholic Fatty Liver Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Non-alcoholic Fatty Liver Disease, historical and forecasted epidemiology as well as the Non-alcoholic Fatty Liver Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Non-alcoholic Fatty Liver Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Non-alcoholic Fatty Liver Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-alcoholic Fatty Liver Disease Market Insights
Non-alcoholic Fatty Liver Disease Overview
Non-alcoholic Fatty Liver Disease (NAFLD) is a very common disorder and refers to a group of conditions where there is accumulation of excess fat in the liver of people who drink little or no alcohol. The most common form of NAFLD is a non-serious condition called fatty liver. In fatty liver, fat accumulates in the liver cells. Although having fat in the liver is not normal, by itself it probably does not damage the liver. A small group of people with NAFLD may have a more serious condition named non-alcoholic steatohepatitis (NASH).
Some of the key facts of the Non-alcoholic Fatty Liver Disease Market Report:
- The Non-alcoholic Fatty Liver Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- According to American Liver Foundation (n.d.), NAFLD is the most common chronic liver condition in the United States
- A study by Golabi et al. (2015), 3,271 NHANES-III participants and the prevalence rates from NAFLD were 40.3% and 39.2% among 60–74 and >74 years old
- According to the study conducted by Foschi et al. (2019), titled, “Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study,” the prevalence of non-alcoholic fatty liver disease (NAFLD) was 0.46 (0.41 to 0.51) vs. 0.22 (0.21 to 0.24) in citizens with than in those without altered liver enzymes
- In January 2022, LISCure Biosciences entered into a research collaboration agreement with Mayo Clinic for new drug development for rare liver diseases
- In September 2022, Inventiva and Chia Tai-Tianqing Pharmaceutical Group entered into a licensing and collaboration agreement to develop and commercialize lanifibranor, if approved, for the treatment of nonalcoholic steatohepatitis and potentially other metabolic diseases in mainland China, Hong Kong, Macau, and Taiwan
- Key Non-alcoholic Fatty Liver Disease Companies: BeiGene, Inventiva Pharma, Cirius Therapeutics, Madrigal Pharma, Novo Nordisk, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Dr. Falk Pharma GmbH, Sagimet Biosciences, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, Novartis Pharmaceuticals, Afimmune, Poxel SA, AngioLab, Pfizer, Oramed Pharmaceuticals, Can Fite Biopharma, MediciNova, Metacrine, Inc., Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma, Chemomab Therapeutics, NuSirt Biopharma, HK inno.N, Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Enanta Pharmaceuticals, Cascade Pharmaceuticals, and others
- Key Non-alcoholic Fatty Liver Disease Therapies: ZSP1603, SCO-267, PXS-5382, PXS-5338, Tolimidone, TT-01025, CER-209, DUR-928, EC-18, ID11903, XW003, CB4211, BLD 0409, NPM-159, TB-019, ABP-6016, Nitazoxanide, TERN-301, Research Programme: NASH, MGAT2 Inhibitors, HSD17B13 targeted therapy, Research Programme: NASH, Resmetirom, Oltipraz, Obeticholic Acid, MSDC-0602K, Tirzepatide, TERN-501/TERN-101, TERN-101, SNP-610, LJN452 (tropifexor + licogliflozin), Epeleuton, PXL065, ALS-L1023, ORMD-0801, MET642, and others
Get a Free sample for the Non-alcoholic Fatty Liver Disease Market Report
Key benefits of the Non-alcoholic Fatty Liver Disease Market report:
- Non-alcoholic Fatty Liver Disease market report covers a descriptive overview and comprehensive insight of the Non-alcoholic Fatty Liver Disease Epidemiology and Non-alcoholic Fatty Liver Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Non-alcoholic Fatty Liver Disease market report provides insights on the current and emerging therapies.
- Non-alcoholic Fatty Liver Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Non-alcoholic Fatty Liver Disease market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Non-alcoholic Fatty Liver Disease market.
Download the report to understand which factors are driving Non-alcoholic Fatty Liver Disease epidemiology trends @ Non-alcoholic Fatty Liver Disease Epidemiological Insights
Non-alcoholic Fatty Liver Disease Market
The dynamics of the Non-alcoholic Fatty Liver Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
Non-alcoholic Fatty Liver Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Non-alcoholic Fatty Liver Disease Epidemiology Segmentation:
The Non-alcoholic Fatty Liver Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Non-alcoholic Fatty Liver Disease
- Prevalent Cases of Non-alcoholic Fatty Liver Disease by severity
- Gender-specific Prevalence of Non-alcoholic Fatty Liver Disease
- Diagnosed Cases of Episodic and Chronic Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-alcoholic Fatty Liver Disease market or expected to get launched during the study period. The analysis covers Non-alcoholic Fatty Liver Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Non-alcoholic Fatty Liver Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major Non-alcoholic Fatty Liver Disease market share @ Non-alcoholic Fatty Liver Disease market forecast
Non-alcoholic Fatty Liver Disease Therapies and Key Companies
- Lanifibranor: Inventiva Pharma
- Belapectin: Galectin Therapeutics
- ZED 1227: Dr. Falk Pharma GmbH
- TVB-2640: Sagimet Biosciences
- ALS-L1023: AngioLab
- MN-001: MediciNova
Scope of the Non-alcoholic Fatty Liver Disease Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Non-alcoholic Fatty Liver Disease Companies: ZSP1603, SCO-267, PXS-5382, PXS-5338, Tolimidone, TT-01025, CER-209, DUR-928, EC-18, ID11903, XW003, CB4211, BLD 0409, NPM-159, TB-019, ABP-6016, Nitazoxanide, TERN-301, Research Programme: NASH, MGAT2 Inhibitors, HSD17B13 targeted therapy, Research Programme: NASH, Resmetirom, Oltipraz, Obeticholic Acid, MSDC-0602K, Tirzepatide, TERN-501/TERN-101, TERN-101, SNP-610, LJN452 (tropifexor + licogliflozin), Epeleuton, PXL065, ALS-L1023, ORMD-0801, MET642, and others
- Key Non-alcoholic Fatty Liver Disease Therapies: BeiGene, Inventiva Pharma, Cirius Therapeutics, Madrigal Pharma, Novo Nordisk, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Dr. Falk Pharma GmbH, Sagimet Biosciences, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, Novartis Pharmaceuticals, Afimmune, Poxel SA, AngioLab, Pfizer, Oramed Pharmaceuticals, Can Fite Biopharma, MediciNova, Metacrine, Inc., Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma, Chemomab Therapeutics, NuSirt Biopharma, HK inno.N, Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Enanta Pharmaceuticals, Cascade Pharmaceuticals, and others
- Non-alcoholic Fatty Liver Disease Therapeutic Assessment: Non-alcoholic Fatty Liver Disease current marketed and Non-alcoholic Fatty Liver Disease emerging therapies
- Non-alcoholic Fatty Liver Disease Market Dynamics: Non-alcoholic Fatty Liver Disease market drivers and Non-alcoholic Fatty Liver Disease market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Non-alcoholic Fatty Liver Disease Unmet Needs, KOL’s views, Analyst’s views, Non-alcoholic Fatty Liver Disease Market Access and Reimbursement
Table of Contents
- Non-alcoholic Fatty Liver Disease Market Report Introduction
- Executive Summary for Non-alcoholic Fatty Liver Disease
- SWOT analysis of Non-alcoholic Fatty Liver Disease
- Non-alcoholic Fatty Liver Disease Patient Share (%) Overview at a Glance
- Non-alcoholic Fatty Liver Disease Market Overview at a Glance
- Non-alcoholic Fatty Liver Disease Disease Background and Overview
- Non-alcoholic Fatty Liver Disease Epidemiology and Patient Population
- Country-Specific Patient Population of Non-alcoholic Fatty Liver Disease
- Non-alcoholic Fatty Liver Disease Current Treatment and Medical Practices
- Non-alcoholic Fatty Liver Disease Unmet Needs
- Non-alcoholic Fatty Liver Disease Emerging Therapies
- Non-alcoholic Fatty Liver Disease Market Outlook
- Country-Wise Non-alcoholic Fatty Liver Disease Market Analysis (2019–2032)
- Non-alcoholic Fatty Liver Disease Market Access and Reimbursement of Therapies
- Non-alcoholic Fatty Liver Disease Market Drivers
- Non-alcoholic Fatty Liver Disease Market Barriers
- Non-alcoholic Fatty Liver Disease Appendix
- Non-alcoholic Fatty Liver Disease Report Methodology
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
To know more about Non-alcoholic Fatty Liver Disease treatment, visit @ Non-alcoholic Fatty Liver Disease Medications
Related Reports:
Non-alcoholic Fatty Liver Disease Pipeline
“Non-alcoholic Fatty Liver Disease Pipeline Insight, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Non-alcoholic Fatty Liver Disease market. A detailed picture of the Non-alcoholic Fatty Liver Disease pipeline landscape is provided, which includes the disease overview and Non-alcoholic Fatty Liver Disease treatment guidelines.
Non-alcoholic Fatty Liver Disease Epidemiology
DelveInsight’s ‘Non-alcoholic Fatty Liver Disease Epidemiology Forecast to 2032‘ report delivers an in-depth understanding of the disease, historical and forecasted Non-alcoholic Fatty Liver Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Related Reports By DelveInsight –
DelveInsight’s “Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight’s “Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight’s “Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
22q11.2 deletion syndrome Market
DelveInsight’s “22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
X-Linked Retinitis Pigmentosa (XLRP) Market
DelveInsight’s “X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Recent Blog’s By DelveInsight:
Other Reports:
- Hip Replacement Devices Market
- Adrenocortical Carcinoma Market
- Acoustic Neuroma Market
- Bone Anchored Hearing Systems Market
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States